UB#WUXI RC2708C

BlackRock Reduces Stake in Wuxi Biologics H-shares to 4.51%

Nordic Nanovector Raises Nearly HK$200 Million Through Rights Issue to WuXi Biologics

Easton Securities Maintains Buy Rating on Wuxi Biologics

J.P. Morgan Raises Wyeth Biologics' Forecast and Target Price

Morgan Stanley Raises Target Price for Wuxi Biologics to 50 HKD

WuXi Biologics Anticipates 16.7% Revenue Growth to 21.79 Billion Yuan in 2025; Gross Margin to Increase by 5 Percentage Points to 46%

WuXi Biologics Reports Preliminary Full Year Net Profit Exceeding Expectations

WuXi Biologics Anticipates Revenue and Gross Margin Growth in 2025

WuXi Biologics Signs Innovative Tri-Specific TCE Development Agreement with Vertex Pharmaceuticals

WuXi Biologics Signs License and Research Agreement for Tri-specific T-cell Engager with Vertex Pharmaceuticals

WuXi Biologics and Sunovian Announce Strategic Collaboration on SND006 Process Development and Manufacturing

Morgan Stanley Reduced Stake in Wuxi Biologics (Cayman)

CLSA Report: Wuxi Biologics Outperforms Peers

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

WuXi Biologics and Zai Lab Sign TCE Research Collaboration Agreement

CCOE

ONEFORCE HLDGS

STARCOIN GROUP

ROYAL DELUXE

WELIFE TECH

DRINDA

ASIAPAC FIN INV

WAI HUNG GROUP

MS CONCEPT

JOHNSON ELEC H

03759

02359

02269

300759

603259

The Lyon Research Report points out that with the development of AI technology, investors' focus has shifted from AI-enabled industries to AI replacing intermediaries, with a more pronounced positive impact expected on comprehensive Contract Research, Development, and Manufacturing Organizations (CRDMO). Lyon is optimistic about Contract Development and Manufacturing Organizations (CDMO), believing that their profit visibility is superior to that of specialized Contract Research Organizations (CRO). Recommended CDMO stocks include WuXi AppTec, WUXI BIO, and Pharmaron, with target prices of 143.4 yuan, 48.5 yuan, and 28.8 yuan, respectively

AASTOCKS

PHARMARON

WUXI APPTEC

WUXI BIO

Pharmaron

WuXi AppTec

In "The Big Banks," Citigroup is optimistic about the profitability visibility of CDMO companies, with WuXi AppTec, WUXI BIO, and Pharmaron as the top choices

159102

159615

520690

513120

02268

520880

159316

Citi released a report stating that WUXI BIO and WUXI XDC fell approximately 7% and 8% respectively on Thursday, while Hong Kong CRO/CDMO companies overall dropped about 2% to 9%. Analysts believe that this decline is not driven by fundamentals, but rather a result of position adjustments and capital flows. The current pullback is viewed as a technical short-term fluctuation, and the lack of catalysts in the market may lead to overselling of industry leaders, providing a more attractive entry point for investors holding for 3 to 12 months

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

WUXI XDC

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

In "The Big Banks," Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers

01299

00005

588130

The Hang Seng Index opened 66 points higher this morning, reporting at 26,447 points. U.S. tech stocks fluctuated due to a sharp decline in NVIDIA, with the Nasdaq down 1.18%. The performance of internet stocks was mixed, with Meituan slightly up 0.68% and Tencent down 0.29%. WuXi Biologics rebounded 4.8%, while HSBC and AIA each rose 1.2%. Southbound funds had a net sell of HKD 7.366 billion in Hong Kong stocks, with some individual stocks like Meituan and Xiaomi seeing net purchases

- U.S. tech stocks declined, with the Nasdaq dropping 2% and the Dow Jones up by 17 points at 49,499.  
- Nvidia's 5% fall marked its third consecutive drop despite surpassing market earnings expectations, impacting other chipmakers like Micron and AMD, which also saw declines.  
- In Hong Kong, the Hang Seng Index opened up 66 points, while notable stocks such as Meituan and Tencent experienced mixed movements, and northbound capital recorded a net sell-off of 7.366 billion HKD in Hong Kong stocks.

Stheadline

HSBC HOLDINGS

HSBC

VanEck Biotech ETF

CSOP HSI ETF

ISHARESHSI

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

Invesco Biotechnology & Genome ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

iShares Biotechnology ETF

The Hang Seng Index opened 66 points higher, WuXi Bio bounced nearly 5%, HSBC and AIA rose over 1% | Hong Kong stock market opens

01072

00501

00100

01038

00001

06160

00914

03750

02611

DONGFANG ELEC(01072) rose 15.52%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 62%. OMNIVISION(00501) rose 6.91%, with a trading turnover 175.0 Million HKD, and a year-to-date rose 4.8%. BEONE MEDICINES(06160) fell 9.16%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 8.4%. WUXI BIO(02269) fell 7.45%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 21.8%.

Top Gainers & Losers

DONGFANG ELEC

OMNIVISION

MINIMAX-WP

CKI HOLDINGS

CKH HOLDINGS

BEONE MEDICINES

CONCH CEMENT

CATL

GTHT

Top 5 HK Stock Gainers/Losers (>100B) (2.26)

00881

02865

03931

00400

02509

02659

02096

ZHONGSHENG HLDG(00881) fell 10.76%, with a trading turnover 324.3 Million HKD, and a year-to-date fell 10.8%. DRINDA(02865) fell 9.32%, with a trading turnover 451.5 Million HKD, and a year-to-date rose 51.2%. CALB(03931) fell 9.26%, with a trading turnover 179.9 Million HKD, and a year-to-date fell 0.1%.

ZHONGSHENG HLDG

CALB

INGDAN

QYUNS-B

BAO PHARMA-B

SIMCERE PHARMA

Top 10 HK Stock Losers (2.26)

520500

WXXWY

Hong Kong's biotech sector experienced a downturn with significant declines in key stocks. According to Jin10, BeiGenesaw a drop of over 9%, while WuXi Biologicsfell more than 7%. Other companies, including WuXi AppTecand Junshi Biosciences, also followed the downward trend. The sector's performance reflects broader market challenges impacting the innovative drug segment.

CoinLive

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

WuXi Biologics

China Universal CNI HK Connect Innovative Drugs Industry ETF

WUXI BIO POFF-D

Beigene

Hong Kong Biotech Stocks Decline as BeiGene and WuXi Biologics Lead Losses

513130

03033

03032

01211

03067

002594

STECH

00285

00HSI

Hong Kong stocks showed significant gains in the morning session, with the Hang Seng Index rising 605 points or 2.3% to 27,019 points. The National Index increased by 224 points, and the Hang Seng Tech Index rose by 173 points. Export, technology, and commodity stocks generally rose, with a total turnover of HKD 106.45 billion. BYD ELECTRONIC, Sunny Optical, and WUXI BIO performed strongly, and the decline of the US dollar also boosted commodity stocks

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

CSOP HS TECH

HSTECH ETF

BYD COMPANY

ISHARESHSTECH

Hang Seng TECH Index

BYD ELECTRONIC

Hang Seng Index

"Hong Kong Stocks" Hang Seng Index rises 605 points in half a day, with export, technology, and commodity stocks up; AI and robotics stocks pull back

02513

09988

03690

The Hong Kong stock market opened higher in the morning, with the Hang Seng Index rising 385 points to 26,798 points, and the National Index and Hang Seng TECH Index increasing by 131 points and 92 points, respectively. E-commerce stocks such as Alibaba and JD opened higher, while technology stocks Tencent, Meituan, and NetEase also saw gains. AI model stock KNOWLEDGE ATLAS opened down 13.8% due to issues. Export stocks such as Creative Technology and SHENZHOU INTL opened higher, and pharmaceutical stocks WUXI BIO and WUXI APPTEC also rose. Commodity prices increased, leading to a general rise in related resource stocks

KNOWLEDGE ATLAS

BABA-W

MEITUAN

SHENZHOU INTL

JD-SW

Alibaba

TENCENT

FI CSOP HSI

FI2CAMNDQ100

FL2 CSOP HSI

China Southern Hang Seng ETF

FI2 CSOP HSI

"Hong Kong Stocks" The Hang Seng Index opened high at 385 points, with technology, export, and resource stocks rising, while AI model stocks retraced

560600

159837

588860

CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limited partnership owned by WuXi Biologics, at a discount to market prices. Proceeds will be used for working capital, R&D, and settling trade payables. The transaction is subject to regulatory approval and reflects ongoing support from WuXi Biologics. The latest analyst rating for CANbridge stock is a Buy with a target price of HK$3.00.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

CANBRIDGE-B

CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit

01698

Hong Kong stocks fell 1.7% to 26,588, marking a second consecutive session of losses due to Wall Street's decline amid AI disruption concerns. China's new home prices dropped 3.3% year-on-year in January, the largest decrease in seven months, impacting market sentiment. All sectors declined, particularly financials, consumer names, and tech. Notable declines included Tencent Music (-9.2%) and Wuxi Biologics (-4.2%). Despite these losses, reports of delayed U.S. tech security measures provided some support. The market showed little change for the week, with trading paused for the Lunar New Year holiday.

- Hong Kong stocks fell 446 points, or 1.7%, to 26,588, influenced by a decline on Wall Street amid AI disruption concerns.  
- China's new home prices decreased by 3.3% year-on-year in January, the largest drop in seven months, impacting property market stability and investor sentiment.  
- Key stocks such as Tencent Music and Wuxi Biologics experienced significant losses, while reports of delayed U.S. tech security measures provided some support ahead of the upcoming U.S.-China summit.

Trading Economics

TME-SW

Tencent Music

Hong Kong Shares Under Pressure, Weekly Performance Muted

Bank of America Securities released a research report, indicating that WUXI BIO is expected to see revenue growth of 16.7% to 21.8 billion yuan in 2025, with gross margin improving to 46%. Net profit is expected to be 5.7 billion, representing a year-on-year growth of 45.3%. The firm raised its target price from HKD 41.8 to HKD 47, maintaining a "Neutral" rating

"Big Banks" Bank of America Securities: WUXI BIO's earnings surprise is stable, raising target price to 47 yuan

00020

09899

09961

MPNGY

The Hong Kong stock market was under pressure in the morning session, with the Hang Seng Index down 242 points, closing at 27,023 points. The National Index fell by 89 points, and the Hang Seng Tech Index dropped by 92 points. Technology stocks generally declined, with Trip.com, Meituan, and NetEase experiencing significant losses. SenseTime rose 5.2% against the trend. Market expectations for a Federal Reserve rate cut have cooled, leading to a slight decline of 66 points in the Dow Jones Industrial Average

SENSETIME-W

NETEASE MUSIC

TRIP.COM-S

Meituan

NTES-S

NetEase

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

UB#WUXI RC2708C(55468.HK)

In "The Big Banks," Citigroup is optimistic about the profitability visibility of CDMO companies, with WuXi AppTec, WUXI BIO, and Pharmaron as the top choices

In "The Big Banks," Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers

The Hang Seng Index opened 66 points higher, WuXi Bio bounced nearly 5%, HSBC and AIA rose over 1% | Hong Kong stock market opens

Top 5 HK Stock Gainers/Losers (>100B) (2.26)

Top 10 HK Stock Losers (2.26)